NSE - SMEListed
Avience Biomedicals Limited
Company websiteThe company Avience Biomedicals Limited has filed papers to raise ₹14,53,800 crore through a public issue. The offering includes a fresh tranche of ₹14,53,800 crore and OFS of ₹0 crore.
Investors may apply between 18-06-2026 and 22-06-2026. Expected allotment is on 23-06-2026 and listing is aimed for 25-06-2026. This is a standard structure — fresh capital for growth, OFS for seller liquidity.
Start Date18-06-2026
End Date22-06-2026
Listing Date25-06-2026
Allotment Date23-06-2026
Current Price₹395.20
GMP₹110 (52.88%)
Lot Size600 Shares
Subscription385.4 Times
Face Value₹10 per share
Listing atNSE
Issue Price₹196 - ₹208
Pre Issue₹40,31,256
Post Issue₹54,85,056
Issue Size₹14,53,800
(aggregating up to 30.24 Cr)
(aggregating up to 30.24 Cr)
Fresh Issue₹14,53,800
(aggregating up to 30.24 Cr)
(aggregating up to 30.24 Cr)
Offer For Sale-
Advertisement
The Grey Market Premium (GMP) for Avience Biomedicals Limited is currently around ₹110 (52.88%). This indicates an estimated listing price of approximately ₹306 based on the latest market sentiment. Please note that GMP values are unofficial and can change frequently as they depend on demand, market conditions, and investor activity.
Gmp Details
| Last Updated | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
24 Jun 2026, 11:09 | ₹208 | ₹90 | ₹298 (43.27%) |
24 Jun 2026, 14:56 | ₹208 | ₹110 | ₹318 (52.88%) |
22 Jun 2026, 10:47 | ₹208 | ₹61 | ₹269 (29.33%) |
23 Jun 2026, 16:46 | ₹208 | ₹80 | ₹288 (38.46%) |
23 Jun 2026, 05:16 | ₹208 | ₹64 | ₹272 (30.77%) |
22 Jun 2026, 10:03 | ₹208 | ₹61 | ₹269 (29.33%) |
16 Jun 2026, 17:42 | ₹208 | ₹55 | ₹263 (26.44%) |
22 Jun 2026, 09:08 | ₹208 | ₹62 | ₹270 (29.81%) |
16 Jun 2026, 12:16 | ₹208 | ₹79 | ₹287 (37.98%) |
15 Jun 2026, 15:39 | ₹208 | ₹59 | ₹267 (28.37%) |
15 Jun 2026, 05:11 | ₹208 | ₹42 | ₹250 (20.19%) |
15 Jun 2026, 04:49 | ₹208 | ₹0 | ₹208 (0.00%) |
Financials overview In Crores
Here is a quick look at the recent financial performance of Avience Biomedicals Limited . The numbers below ( In Crores ) show how the company’s revenue and profits have changed over the last few years. This helps investors understand how strongly the business is growing and how stable its financial health is before applying for the IPO.
Key Performance
| KPI | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
EPS | 14.24 | 19.06 | 6.52 |
ROE | 22.38 | 49.89 | 34.47 |
ROCE | 16.99 | 24.88 | 17.97 |
RONW | 0 | 0 | 0 |
PRE IPO(PE) | 0 | 11.59 | 0 |
POST IPO(PE) | 16.56 | 0 | 0 |
Subscription Details (No. of Shares)
The below shows how many shares were subscribed by each investor category in the Avience Biomedicals Limited IPO. These numbers help you understand where the demand is coming from – whether it’s retail investors, QIBs, or NIBs. Higher subscription usually indicates strong interest and confidence from the market.
Subscription Demand (in ₹ Crore)
| Category | Offered | Demand | Times |
|---|---|---|---|
QIBs | ₹5.69 | 1119.82 | 196.80 |
FIIs | ₹0 | 195.21 | 0.00 |
FIs | ₹0 | 139.51 | 0.00 |
Mutual Funds | ₹0 | 18.7 | 0.00 |
Others | ₹0 | 766.4 | 0.00 |
RETAIL | ₹10.01 | 4017.16 | 401.31 |
HNIs 2+ | ₹1.44 | 647.77 | 449.84 |
HNIs 10+ | ₹2.87 | 1925.39 | 670.87 |
Total | ₹20.01 | 7710.14 | 385.31 |
Application Wise Breakup (Approx. no of Apps)
| Category | Reserved | Applied | Times |
|---|---|---|---|
QIB | 0 | 172 | 0.00 |
NIB | 0 | 31,836 | 0.00 |
RETAIL | 401 | 1,60,944 | 401.36 |
HNIs(10L +) | 77 | 16,492 | 214.18 |
HNIs (2-10L) | 38 | 15,344 | 403.79 |
Total | 516 | 1,92,780 | 373.60 |
The IPO reservation for Avience Biomedicals Limited shows how the total issue is divided among different investor categories. This includes allocations for Retail Investors, Qualified Institutional Buyers (QIBs), and Non-Institutional Investors (NIIs). Understanding the reservation structure helps investors know how much of the issue is set aside for their category before applying.
IPO Reservation
| Category | Shares Offers | No. of Shares |
|---|---|---|
Anchor | 28.19% | 4,09,800 |
QIB | 18.82% | 2,73,600 |
HNI | 14.24% | 2,07,000 |
RETAIL | 33.10% | 4,81,200 |
Market Maker | 5.65% | 82,200 |
TOTAL | 100.00% | 14,53,800 |
Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
Retail (Min) | 2 | 1,200 | ₹2,49,600 | |
sHNI | 3 | 1,800 | ₹3,74,400 | |
bHNI | 9 | 5,400 | ₹11,23,200 |
Below you can find the official contact details of Avience Biomedicals Limited along with the registrar handling the IPO process. This information helps investors reach out for queries related to the company or for checking the allotment status and application updates once the IPO process begins.
Company Details
Email: info@avienbio.com
Phone: 1800-12-04-636
Website: https://avienbio.com/
Address: C-11, Block-C Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
IPO Registrar
Name: Skyline Financial Services Private Limited
Phone: +912228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php
Advertisement